Patents by Inventor Patricia M. Logan
Patricia M. Logan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120003297Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: ApplicationFiled: February 1, 2011Publication date: January 5, 2012Applicant: TALON THERAPEUTICS, INC.Inventors: Andreas SARRIS, Fernando CABANILLAS, Patricia M. LOGAN, Clive T.R. BURGE, James H. GOLDIE, Murray S. WEBB
-
Patent number: 7887836Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: GrantFiled: March 7, 2008Date of Patent: February 15, 2011Assignees: Hana Biosciences, Inc., Board of Regents, The University of Texas SystemInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb
-
Patent number: 7504228Abstract: Methods are provided to specifically modulate the activation of monocytes and/or macrophages. Administration of integrin linked kinase (ILK) blocking agents; compounds that otherwise prevent the binding of natural ILK ligands to ILK; or compounds that prevent expression of, or signaling through ILK exert an anti-inflammatory effect by inhibiting iNOS and COX-2 expression, at the level of transcription by suppressing the activation of NF-?B. The modulation of activation through ILK is used to regulate immune processes at targeted sites, for example to decrease undesirable inflammatory responses.Type: GrantFiled: June 5, 2002Date of Patent: March 17, 2009Assignee: QLT Inc.Inventors: Ljiljana Kojic, Patricia M. Logan, Jeffery J. Wheeler, Kymberley L. Sutton, Gabriel Bela Kalmar
-
Publication number: 20090041834Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: ApplicationFiled: March 7, 2008Publication date: February 12, 2009Applicants: Inex Pharmaceuticals Corporation, Board of Regents, The University of Texas SystemInventors: Andreas SARRIS, Fermando CABANILLAS, Patricia M. LOGAN, Clive T.R. BURGE, James H. GOLDIE, Murray S. WEBB
-
Patent number: 7311924Abstract: This invention provides compositions and methods for treating neoplasias in a mammal. In particular, the invention provides liposome-encapsulated vinca alkaloids, e.g., vinorelbine, and methods of treating a mammal using such compositions.Type: GrantFiled: April 3, 2003Date of Patent: December 25, 2007Assignee: Hana Biosciences, Inc.Inventors: Andreas H Sarris, Fernando Cabanillas, Patricia M Logan, Clive T R Burge, James H Goldie, Murray S Webb, Thomas D Madden, Sean C Semple, Quet F Ahkong, Sandra K Klimuk
-
Patent number: 7247316Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: GrantFiled: February 18, 2004Date of Patent: July 24, 2007Assignees: Board of Regents, The University of Texas System, Inex Pharmaceuticals CorporationInventors: Andreas H Sarris, Fernando Cabanillas, Patricia M Logan, Clive T R Burge, James H Goldie, Murray S Webb
-
Patent number: 7244450Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: GrantFiled: December 4, 2003Date of Patent: July 17, 2007Assignees: Inex Pharmaceuticals Corporation, Board of Regents, The University of Texas SystemInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb
-
Publication number: 20040253302Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: ApplicationFiled: December 4, 2003Publication date: December 16, 2004Applicants: Board of Regents, The University of Texas System, Inex Pharmaceuticals CorporationInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T.R. Burge, James H. Goldie, Murray S. Webb
-
Publication number: 20040228909Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: ApplicationFiled: February 18, 2004Publication date: November 18, 2004Applicants: Inex Pharmaceuticals Corporation, Board of Regents, The University of Texas SystemInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb
-
Patent number: 6723338Abstract: This invention provides methods for treating neoplasias in a mammal. In particular, the invention provides methods for treating various types of lymphomas, including relapsed forms of non-Hodgkin's Lymphoma. These methods involve the administration of liposome-encapsulated vinca alkaloids, e.g., vincristine, to a mammal with a lymphoma.Type: GrantFiled: March 31, 2000Date of Patent: April 20, 2004Assignees: Inex Pharmaceuticals Corporation, Board of Regents, The University of Texas SystemInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb
-
Publication number: 20040071768Abstract: This invention provides compositions and methods for treating neoplasias in a mammal. In particular, the invention provides liposome-encapsulated vinca alkaloids, e.g., vinorelbine, and methods of treating a mammal using such compositions.Type: ApplicationFiled: April 3, 2003Publication date: April 15, 2004Applicants: Inex Pharmaceuticals Corporation, The University of Texas, MD Anderson Cancer CenterInventors: Andreas H. Sarris, Fernando Cabanillas, Patricia M. Logan, Clive T. R. Burge, James H. Goldie, Murray S. Webb, Thomas D. Madden, Sean C. Semple, Quet F. Ahkong, Sandra K. Klimuk
-
Patent number: 5597722Abstract: The present invention provides a method for inactivating pathogens in a body fluid, such as plasma, red cells, platelets, leukocytes, and bone marrow. The present invention minimizes adverse effects caused by the photosensitive agents while retaining the disinfecting activity of such agents and processes. Pursuant to the present invention, prior to irradiating a body fluid including a photoactive drug, the extracellular fluid, which in the case of blood components includes plasma proteins is at least substantially reduced. Additionally, after the irradiation process, the resultant body fluid is prevented from contacting additional extracellular fluid, e.g., plasma proteins, for a predefined period.Type: GrantFiled: July 13, 1994Date of Patent: January 28, 1997Assignee: Baxter International Inc.Inventors: John Chapman, Patricia M. Logan, Herma C. Neyndorff, Janice North
-
Patent number: 5422362Abstract: A method to inhibit the development of intimal hyperplasia following vascular intervention procedures (angioplasty) is disclosed. The method consists essentially of administering a green porphyrin to the subject concurrent with and following the angioplasty. No purposeful irradiation with light absorbed by the green porphyrin is required or employed in the method.Type: GrantFiled: July 29, 1993Date of Patent: June 6, 1995Assignee: Quadra Logic Technologies, Inc.Inventors: G. Michael Vincent, Patricia M. Logan
-
Patent number: 5360734Abstract: The present invention provides a method for inactivating pathogens in a body fluid, such as plasma, red cells, platelets, leukocytes, and bone marrow. The present invention minimizes adverse effects caused by the photosensitive agents while retaining the disinfecting activity of such agents and processes. Pursuant to the present invention, prior to irradiating a body fluid including a photoactive drug, the extracellular fluid, which in the case of blood components includes plasma proteins is at least substantially reduced. Additionally, after the irradiation process, the resultant body fluid is prevented from contacting additional extracellular fluid, e.g., plasma proteins, for a predefined period.Type: GrantFiled: January 28, 1993Date of Patent: November 1, 1994Assignees: Baxter International, Inc., Quadra Logic Technologies, Inc.Inventors: John Chapman, Patricia M. Logan, Herma C. Neyndorff, Janice North
-
Patent number: D384556Type: GrantFiled: February 29, 1996Date of Patent: October 7, 1997Inventors: Patricia M. Logan, Laura Brooks